GTO ID | GTC2861 |
Trial ID | NCT05143307 |
Disease | HIV Infection |
Altered gene | HSV-1 genome |
Therapeutic/Target gene | Target gene |
Therapy | Gene editing |
Treatment | EBT-101 |
Phase | Phase1 |
Recruitment status | Enrolling By Invitation |
Title | Long-Term Follow-Up Study of HIV-1 Infected Adults Exiting a Parent Study Where EBT-101 Was Administered |
Year | 2021 |
Country | United States |
Company sponsor | Excision BioTherapeutics |
Other ID(s) | EBT-101-002 |
Vector information | |||||||||
|
Cohort 1 | |||||||
|